In order to fight cancer, there are different approaches to deal with abnormal cell growth. While traditional chemotherapy focuses on rapidly dividing cells, there are target therapies that focus on biological pathways needed to facilitate tumor development. The targeted therapy Bevacizumab 400 mg is one of them that can be used for the treatment of colorectal cancer. This medicine does not destroy cancer cells but inhibits Vascular Endothelial Growth Factor (VEGF).

Why Is VEGF Important for Colorectal Cancer Growth?  

During the progression of colorectal cancers, they need to have an adequate supply of oxygen and nutrients. VEGF is one of the factors that play a critical role in angiogenesis, the formation of new blood vessels. Cancers are able to secrete VEGF to stimulate the formation of blood vessels. It provides an environment in which cancers develop. Hence, targeting VEGF provides another strategy to deal with colorectal cancer.

How Does Bevacizumab 400 mg Block VEGF Activity?  

The medicine is a monoclonal antibody that binds to VEGF-A in order to inhibit interactions between VEGF-A and receptors. Inhibiting interactions hinders signaling for the formation of new blood vessels. However, mechanism of action includes:

• Binding of VEGF: The medicine binds to VEGF-A and prevents activation of receptors.

• Inhibition of angiogenesis: It inhibits formation of new blood vessels which promote tumor growth.

• Restriction of tumor nutrition: Formation of blood vessels associated with tumors provides nutrients and oxygen for cancerous tissue.

Therefore, the injection, unlike chemotherapeutic drugs, does not target fast-dividing cancer cells but rather interferes with biological processes which contribute to tumor growth.

Why Is The Injection Combined with Chemotherapy?  

In addition to chemotherapy drugs, Bevacizumab Injection in colorectal cancer is one of the effective treatment as recommended by the doctor. Chemotherapy is designed to attack the actively growing cells while this medicine works to inhibit blood vessels formed due to the VEGF factor. The choice of therapy depends upon the features of cancer and the patient’s general condition.

Conclusion

The use of the injection in the treatment of colon cancers is due to the fact that it is a specific medication, which blocks the action of VEGF-A and angiogenesis within the tumours. The ability of the drug to disrupt the formation of blood vessels means that it plays a significant role in certain chemotherapies.

FAQs

1. Does the Injection directly kill the colorectal cancer cells?

No, it does not directly kill the cancer cells. It inhibits VEGF-A, thereby preventing the development of the blood vessels supporting the tumour.

2. What are some common Bevacizumab side effects?

Some common side effects include high blood pressure, nose bleeds, headache, tiredness, and protein in urine. The serious side effects could be bleeding, blood clots, kidney problems, and poor wound healing.